Meflotas Tablet (Mefloquine 250mg)

What is Meflotas Tablet (Mefloquine 250mg)?

Meflotas Tablet (Mefloquine 250mg) is a prescription medication containing mefloquine hydrochloride, an antimalarial drug used to prevent and treat malaria caused by Plasmodium species, including chloroquine-resistant strains. It works by interfering with the parasite's ability to break down hemoglobin in red blood cells, effectively stopping its replication. Meflotas is typically taken once weekly, starting before travel to a malaria-prone region, continuing during the stay, and for several weeks after leaving.

Key features

• Active Ingredient — Mefloquine 250mg as hydrochloride salt for effective antimalarial action.
• Dosing Schedule — Once-weekly regimen improves adherence compared to daily alternatives.
• Malaria Prevention — Effective against chloroquine-resistant Plasmodium falciparum in high-risk zones.
• Travel-Ready — Suitable for long-term travelers and expatriates in endemic regions.
• Prescription-Based — Requires medical evaluation due to neurological and psychiatric risk profile.
• Stable Formulation — Tablet form ensures consistent dosage and shelf life under proper storage.
• Global Use — Widely distributed in tropical and subtropical regions with malaria transmission.

Who is Meflotas Tablet (Mefloquine 250mg) for?

This medication is intended for adults and children weighing over 45 kg traveling to or living in areas with high rates of chloroquine-resistant malaria. It is not recommended for individuals with a history of seizures, depression, or other psychiatric disorders. Pregnant women should consult a physician before use. Ideal users include long-term travelers, aid workers, and military personnel deployed to endemic zones.

How does Meflotas Tablet (Mefloquine 250mg) compare?

Compared to daily antimalarials like doxycycline or Malarone, Meflotas offers a weekly dosing advantage, improving convenience and compliance. However, it carries a higher risk of neuropsychiatric side effects than atovaquone-proguanil. Unlike fast-acting treatments such as artemisinin-based combination therapies (ACTs), Meflotas is not used for acute malaria episodes but rather for prophylaxis. It remains a cost-effective option in regions where resistance patterns favor its use.